Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.

PsoriasisRheumatoid Arthritis

Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.

Skin Therapy Lett.

Gupta AK, Cernea M, Lynde CW

Psoriasis

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials

Br J Dermatol.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R

doi: 10.1111/bjd.17149.

PsoriasisPsoriatic ArthritisRheumatoid Arthritis

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Expert Rev Clin Immunol.

Berekmeri A, Mahmood F, Wittmann M, Helliwell P

doi: 10.1080/

Psoriasis

Tofacitinib: A New Oral Therapy for Psoriasis

Clin Drug Investig.

Azevedo A, Torres T

doi: 10.1007/s40261-017-0596-y.

Atopic Dermatitis

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial

JAMA Dermatol.

Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E

doi: 10.1001/jamadermatol.2019.2855.

RECOMMENDED

Psoriasis

Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France

Ann Dermatol Venereol.

Tournier A, Khemis A, Maccari F, Reguiai Z, Bégon E, Fougerousse AC, Amy de la Breteque M, Beneton N, Parier J, Boyé T, Avenel-Audran M, Girard C, Pallure V, Perrot JL, Bastien M, Mahé E, Beauchet A; GEM Resopso

doi: 10.1016/j.annder.2018.11.011.

COMMENTED

Rheumatoid Arthritis

Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Clin Rheumatol.

Kunwar S, Collins CE, Constantinescu F

doi: 10.1007/s10067-018-4199-7.

PsoriasisPsoriatic Arthritis

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials

J Eur Acad Dermatol Venereol.

Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR

doi: 10.1111/jdv.13918.

Psoriasis

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

J Eur Acad Dermatol Venereol.

Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U, CHANGE investigator group.

doi: 10.1111/jdv.16932.

Related content

Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Tofacitinib: A New Oral Therapy for Psoriasis

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial

Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France

Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)